Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate + metformin fixed combination vs rosiglitazone in drug-naïve type 2 diabetes mellitus with dyslipidemia
2005-006060-63Phase 3Terminated
- Sponsor
- Fournier
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and dyslipidemia comparing Fenofibrate + metformin fixed combination with Rosiglitazone monotherapy (2 arms). Primary endpoints: Primary efficacy endpoints at 12 weeks and Primary objective at 24 weeks. Started Mar 2006; status: terminated.
02
Drugs
fenofibratemetforminrosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on 2005-006060-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006060-63.